Accession Number : AD1000370


Title :   Molecular Characterization of Human MUC16 (CA125) in Breast Cancer


Descriptive Note : Technical Report


Corporate Author : University of Nebraska Medical Center Omaha, United States


Personal Author(s) : Das,Srustidhar


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1000370.pdf


Report Date : 01 Apr 2015


Pagination or Media Count : 35


Abstract : MUC16, precursor of the most widely used ovarian cancer biomarker CA125, is up-regulated in multiple malignancies and is associatedwith poor prognosis. While the pro-tumorigenic and metastatic roles of MUC16 are ascribed to the cell-associated carboxyl-terminalMUC16 (MUC16-Cter), the exact biochemical nature of MUC16 cleavage generating MUC16-Cter has remained unknown. Using differentlengths of dual-epitope (N-terminal FLAG- and C-terminal HA-Tag) tagged C-terminal MUC16 fragments, we demonstrate that MUC16cleavage takes place in the juxta-membrane ectodomain stretch of twelve amino acids that generates a 17 kDa cleaved product and isdistinct from the predicted sites. This was further corroborated by domain swapping experiment. Further, the cleavage of MUC16 wasfound to take place in the Golgi/post-Golgi compartments and is dependent on the acidic pH in the secretory pathway. A similar pattern of17 kDa cleaved MUC16 was observed in multiple cell types eliminating the possibility of cell type specific phenomenon. MUC16-Ctertranslocates to the nucleus in a cleavage dependent manner and binds to the chromatin suggesting its involvement in regulation of geneexpression. Taken together, we demonstrate for the first time the oft-predicted cleavage of MUC16 that is critical in devising successfultherapeutic interventions based on MUC16.


Descriptors :   biological markers , breast cancer , molecules , cells(biology) , medical research , ovarian cancer , membranes


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE